Genfit S.A.
GNFT.PADrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
GFT505 80mg
Type II Diabetes Mellitus
GNS561 + Trametinib
Cholangiocarcinoma
GFT505 120mg
Non-Alcoholic Steatohepatitis (NASH)
Elafibranor 80 mg
Primary Biliary Cholangitis (PBC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GFT505 80mg | Phase 2 | Type II Diabetes Mellitus | - | - |
GNS561 + Trametinib | Phase 2 | Cholangiocarcinoma | - | - |
GFT505 120mg | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Elafibranor 80 mg | Phase 2 | Primary Biliary Cholangitis (PBC) | - | - |
Frequently asked questions
What is in Genfit S.A.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Genfit S.A.'s (GNFT.PA) pipeline across Phase 2. Its lead program is GFT505 80mg (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genfit S.A.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Genfit S.A. (GNFT.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GNFT.PA biotech catalysts?→
Add GNFT.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genfit S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.